![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Telkom Indonesia Persero Tbk PT | TG:PTI | Tradegate | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 17.10 | 17.00 | 17.10 | 0.00 | 17:37:23 |
RNS Number:6553L Protherics PLC 29 May 2003 Not for release, publication or distribution in or into the United States, Canada, Australia or Japan Recommended Offer By WestLB Panmure Limited ("Panmure") On behalf of Protherics PLC ("Protherics") To acquire the whole of the issued and to be issued share capital of Enact Pharma plc ("Enact") Offer declared unconditional as to acceptances Panmure is pleased to announce on behalf of Protherics that the Offer to acquire the entire share capital of Enact has been declared unconditional as to acceptances and will remain open until further notice. Not less than 14 days' notice will be given prior to the closing of the Offer. The Offer remains conditional on the UK Listing Authority agreeing to admit the Protherics Placing Shares to the Official List and the London Stock Exchange agreeing to admit these shares to trading on its market for listed securities. At 3.00 p.m. on 28 May 2003, the first closing date of the Offer, valid acceptances of the Offer had been received in respect of a total of 36,203,180 Enact Shares, representing approximately 85.7 per cent. of Enact's current issued share capital and approximately 85.7 per cent. of the Enact Shares to which the Offer relates. None of such acceptances have been received from persons acting in concert with Protherics. Prior to the commencement of the Offer, irrevocable undertakings to accept the Offer had been received in respect of, in aggregate, 11,612,830 Enact Shares, representing 27.5 per cent. of Enact's issued share capital. In addition, Protherics received a non-binding letter of intent to accept the Offer in respect of a further 10,004,277 Enact Shares representing 23.7 per cent. of Enact's issued share capital. Valid acceptances have been received in respect of all of these shares subject to these undertakings and the letter of intent and are included in the above total. Other than as set out above, neither Protherics nor any person acting, or deemed to be acting, in concert with it held any Enact Shares as at 1 May 2003, the day before the commencement of the Offer Period, or has acquired or agreed to acquire any Enact Shares (or rights over such shares) during the Offer Period. Upon Protherics receiving acceptances under the Offer in respect of, and/or otherwise acquiring, 90 per cent. or more of the Enact Shares to which the Offer relates, Protherics intends to exercise its rights pursuant to the provisions of sections 428 to 430F of the Act to acquire compulsorily Enact Shares to which the Offer relates. As described in the Offer Document, once the Offer becomes unconditional in all respects, Protherics intends to procure the making of an application by Enact to OFEX for the cancellation of the trading in Enact Shares. Cancellation of the Enact listing will not take place until at least 20 Business Days after the date when notice of its intention to seek the cancellation of Enact's listing is given. Enact Shareholders who wish to accept the Offer, and who have not done so, should return the Form(s) of Acceptance as soon as possible. Further Forms of Acceptances can be obtained from Neville Registrars Limited, Neville House, 18 Laurel Lane, Halesowen, West Midlands B63 3DA (tel: 0121 585 1131). Terms defined in the Offer Document dated 7 May have the same meaning in this press release unless the context otherwise requires. 29 May 2003 Protherics PLC 020 7246 9950 Andrew Heath, Chief Executive Barry Riley, Finance Director WestLB Panmure Limited 020 7020 4000 Juliet Thompson Enact Pharma plc James Cooper 07740 835289 The Maitland Consultancy 020 7379 5151 Brian Hudspith Simone Cheetham WestLB Panmure Limited, which is regulated in the United Kingdom by The Financial Services Authority, is acting exclusively for Protherics in connection with the Offer and no-one else and will not be responsible to anyone other than Protherics for providing the protections afforded to customers of WestLB Panmure Limited, nor for giving advice in relation to the Offer. This information is provided by RNS The company news service from the London Stock Exchange END OUPBIGDUSGDGGXI
1 Year Telkom Indonesia Persero... Chart |
1 Month Telkom Indonesia Persero... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions